PYC Therapeutics Financials
PYC Stock | 1.40 0.05 3.45% |
Operating Margin (1.78) | Profit Margin (1.71) | EPS Estimate Current Year (0.01) | Return On Equity (0.70) |
PYC | Select Account or Indicator |
Please note, the imprecision that can be found in PYC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PYC Therapeutics. Check PYC Therapeutics' Beneish M Score to see the likelihood of PYC Therapeutics' management manipulating its earnings.
PYC Therapeutics Stock Summary
PYC Therapeutics competes with FSA, Tamawood, Cochlear, Rea, and Macquarie. PYC Therapeutics is entity of Australia. It is traded as Stock on AU exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | Australia Stock View All |
Exchange | Australian Securities Exchange |
ISIN | AU000000PYC7 |
Business Address | Harry Perkins Inst |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | pyctx.com |
Phone | 61 8 6151 0992 |
You should never invest in PYC Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of PYC Stock, because this is throwing your money away. Analyzing the key information contained in PYC Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
PYC Therapeutics Key Financial Ratios
PYC Therapeutics' financial ratios allow both analysts and investors to convert raw data from PYC Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of PYC Therapeutics over time and compare it to other companies across industries.Revenue | 22.06 M | ||||
Gross Profit | 15.81 M | ||||
EBITDA | (38.12 M) | ||||
Net Income | (37.73 M) | ||||
Cash And Equivalents | 15.57 M |
PYC Therapeutics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 31.5M | 57.9M | 45.4M | 37.2M | 91.2M | 95.8M | |
Other Current Liab | 455.3K | 763.3K | 1.6M | 3.3M | 1.3M | 1.3M | |
Accounts Payable | 97.3K | 2.3M | 2.6M | 4.9M | 7.5M | 7.9M | |
Cash | 7.2M | 18.4M | 29.1M | 15.6M | 66.9M | 70.2M | |
Net Receivables | 82.7K | 185.6K | 10.1M | 16.3M | 18.0M | 18.9M | |
Total Liab | 1.4M | 4.0M | 5.1M | 8.7M | 10.2M | 10.7M | |
Common Stock | 62.0M | 87.2M | 126.0M | 140.1M | 230.6M | 242.1M | |
Net Debt | (6.4M) | (17.7M) | (28.2M) | (15.3M) | (65.8M) | (62.5M) | |
Retained Earnings | (63.7M) | (81.5M) | (95.4M) | (118.2M) | (155.9M) | (148.1M) | |
Other Current Assets | 50.4K | 93.1K | 68.4K | 49.6K | 744.0K | 781.2K | |
Total Current Assets | 25.6M | 51.8M | 39.2M | 31.9M | 85.6M | 89.9M | |
Net Tangible Assets | 23.1M | 48.4M | 34.9M | 23.5M | 27.0M | 17.3M | |
Long Term Debt Total | 645.2K | 542.8K | 684.0K | 137.7K | 158.3K | 315.8K | |
Net Invested Capital | 28.0M | 52.5M | 39.4M | 27.7M | 80.5M | 84.5M | |
Cash And Equivalents | 7.2M | 18.4M | 29.1M | 15.6M | 17.9M | 14.1M | |
Net Working Capital | 24.6M | 48.5M | 34.9M | 23.5M | 76.5M | 80.3M |
PYC Therapeutics Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 42.9K | 38.8K | 32.6K | 27.3K | 49.2K | 51.7K | |
Cost Of Revenue | 547.1K | 622.4K | 839.5K | 882.0K | 1.1M | 1.5M | |
Total Revenue | 2.4M | 3.1M | 16.0M | 15.8M | 22.1M | 23.2M | |
Gross Profit | 1.8M | 2.5M | 15.2M | 14.9M | 22.1M | 23.2M | |
Operating Income | (9.7M) | (21.8M) | (30.2M) | (39.2M) | (38.9M) | (36.9M) | |
Ebit | (9.4M) | (21.7M) | (30.2M) | (39.1M) | (39.2M) | (37.2M) | |
Research Development | 5.9M | 14.0M | 24.0M | 35.1M | 56.4M | 59.2M | |
Ebitda | (8.9M) | (21.0M) | (29.4M) | (38.3M) | (38.1M) | (36.2M) | |
Income Before Tax | (9.5M) | (21.7M) | (30.3M) | (39.2M) | (55.7M) | (52.9M) | |
Net Income | (6.8M) | (17.8M) | (13.9M) | (22.8M) | (37.7M) | (35.8M) | |
Income Tax Expense | (2.4M) | (3.1M) | (16.0M) | (15.8M) | (17.6M) | (16.7M) | |
Interest Income | 207.0K | 108.5K | 24.4K | 81.8K | 796.0K | 835.8K | |
Net Interest Income | 207.0K | 69.7K | (8.2K) | 54.6K | 746.8K | 784.1K |
PYC Therapeutics Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Capital Expenditures | 106.1K | 591.0K | 386.9K | 491.1K | 307.0K | 224.6K | |
End Period Cash Flow | 7.2M | 18.4M | 29.1M | 15.6M | 66.9M | 70.2M | |
Change In Cash | 1.1M | 11.2M | 10.7M | (13.5M) | 51.3M | 53.9M | |
Free Cash Flow | (5.9M) | (12.4M) | (22.2M) | (24.9M) | (38.9M) | (37.0M) | |
Depreciation | 547.1K | 622.4K | 839.5K | 882.0K | 1.1M | 1.1M | |
Other Non Cash Items | 1.6M | 1.6M | 11.5M | 3.0M | 229.1K | 217.6K | |
Net Income | (6.8M) | (17.8M) | (13.9M) | (22.8M) | (37.7M) | (35.8M) | |
Change To Netincome | 472.0K | 2.8M | 182.2K | (554.2K) | (637.4K) | (605.5K) | |
Change To Inventory | 1.0 | (2.7M) | (892.8K) | (4.2M) | (3.8M) | (3.6M) | |
Investments | (13.7M) | (14.9M) | 33.1M | (477.1K) | (307.0K) | (322.4K) |
PYC Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PYC Therapeutics's current stock value. Our valuation model uses many indicators to compare PYC Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PYC Therapeutics competition to find correlations between indicators driving PYC Therapeutics's intrinsic value. More Info.PYC Therapeutics is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PYC Therapeutics' earnings, one of the primary drivers of an investment's value.PYC Therapeutics Systematic Risk
PYC Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PYC Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on PYC Therapeutics correlated with the market. If Beta is less than 0 PYC Therapeutics generally moves in the opposite direction as compared to the market. If PYC Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PYC Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PYC Therapeutics is generally in the same direction as the market. If Beta > 1 PYC Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
PYC Therapeutics Total Assets Over Time
PYC Therapeutics December 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PYC Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PYC Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of PYC Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing PYC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PYC Therapeutics's daily price indicators and compare them against related drivers.
Information Ratio | (0.01) | |||
Maximum Drawdown | 25.32 | |||
Value At Risk | (7.69) | |||
Potential Upside | 5.71 |
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.